Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Muscle IL1β Drives Ischemic Myalgia via ASIC3-Mediated Sensory Neuron Sensitization.

Ross JL, Queme LF, Cohen ER, Green KJ, Lu P, Shank AT, An S, Hudgins RC, Jankowski MP.

J Neurosci. 2016 Jun 29;36(26):6857-71. doi: 10.1523/JNEUROSCI.4582-15.2016.

2.

Structure and function of chicken interleukin-1 beta mutants: uncoupling of receptor binding and in vivo biological activity.

Chen WT, Huang WY, Chen T, Salawu EO, Wang D, Lee YZ, Chang YY, Yang LW, Sue SC, Wang X, Yin HS.

Sci Rep. 2016 Jun 9;6:27729. doi: 10.1038/srep27729.

3.

Generation and Characterization of Mice Expressing a Conditional Allele of the Interleukin-1 Receptor Type 1.

Robson MJ, Zhu CB, Quinlan MA, Botschner DA, Baganz NL, Lindler KM, Thome JG, Hewlett WA, Blakely RD.

PLoS One. 2016 Mar 1;11(3):e0150068. doi: 10.1371/journal.pone.0150068. eCollection 2016.

4.

Conformational Sampling and Binding Site Assessment of Suppression of Tumorigenicity 2 Ectodomain.

Yang CY, Delproposto J, Chinnaswamy K, Brown WC, Wang S, Stuckey JA, Wang X.

PLoS One. 2016 Jan 6;11(1):e0146522. doi: 10.1371/journal.pone.0146522. eCollection 2016.

5.

The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.

Rondeau JM, Ramage P, Zurini M, Gram H.

MAbs. 2015;7(6):1151-60. doi: 10.1080/19420862.2015.1081323. Epub 2015 Aug 18.

6.

Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes.

Spohn G, Schori C, Keller I, Sladko K, Sina C, Guler R, Schwarz K, Johansen P, Jennings GT, Bachmann MF.

Mol Ther Methods Clin Dev. 2014 Oct 22;1:14048. doi: 10.1038/mtm.2014.48. eCollection 2014.

7.
8.

The structural basis for receptor recognition of human interleukin-18.

Tsutsumi N, Kimura T, Arita K, Ariyoshi M, Ohnishi H, Yamamoto T, Zuo X, Maenaka K, Park EY, Kondo N, Shirakawa M, Tochio H, Kato Z.

Nat Commun. 2014 Dec 15;5:5340. doi: 10.1038/ncomms6340.

9.

Preparation of Soluble Proteins from Escherichia coli.

Wingfield PT.

Curr Protoc Protein Sci. 2014 Nov 3;78:6.2.1-22. doi: 10.1002/0471140864.ps0602s78. Review.

10.

Protein painting reveals solvent-excluded drug targets hidden within native protein-protein interfaces.

Luchini A, Espina V, Liotta LA.

Nat Commun. 2014 Jul 22;5:4413. doi: 10.1038/ncomms5413.

11.

Arabidopsis genes, AtNPR1, AtTGA2 and AtPR-5, confer partial resistance to soybean cyst nematode (Heterodera glycines) when overexpressed in transgenic soybean roots.

Matthews BF, Beard H, Brewer E, Kabir S, MacDonald MH, Youssef RM.

BMC Plant Biol. 2014 Apr 16;14:96. doi: 10.1186/1471-2229-14-96.

12.

Structural biology of the IL-1 superfamily: key cytokines in the regulation of immune and inflammatory responses.

Krumm B, Xiang Y, Deng J.

Protein Sci. 2014 May;23(5):526-38. doi: 10.1002/pro.2441. Epub 2014 Mar 4. Review.

13.

Structural insights into the interaction of IL-33 with its receptors.

Liu X, Hammel M, He Y, Tainer JA, Jeng US, Zhang L, Wang S, Wang X.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):14918-23. doi: 10.1073/pnas.1308651110. Epub 2013 Aug 26.

14.

Altered backbone and side-chain interactions result in route heterogeneity during the folding of interleukin-1β (IL-1β).

Capraro DT, Lammert H, Heidary DK, Roy M, Gross LA, Onuchic JN, Jennings PA.

Biophys J. 2013 Aug 20;105(4):975-83. doi: 10.1016/j.bpj.2013.06.019.

15.

Understanding the folding-function tradeoff in proteins.

Gosavi S.

PLoS One. 2013 Apr 12;8(4):e61222. doi: 10.1371/journal.pone.0061222. Print 2013.

16.

Allosteric switching of agonist/antagonist activity by a single point mutation in the interluekin-1 receptor antagonist, IL-1Ra.

Hailey KL, Capraro DT, Barkho S, Jennings PA.

J Mol Biol. 2013 Jul 10;425(13):2382-92. doi: 10.1016/j.jmb.2013.03.016. Epub 2013 Mar 15.

17.

Molecular basis of NF-κB signaling.

Napetschnig J, Wu H.

Annu Rev Biophys. 2013;42:443-68. doi: 10.1146/annurev-biophys-083012-130338. Epub 2013 Mar 11. Review.

18.

Design of a superior cytokine antagonist for topical ophthalmic use.

Hou J, Townson SA, Kovalchin JT, Masci A, Kiner O, Shu Y, King BM, Schirmer E, Golden K, Thomas C, Garcia KC, Zarbis-Papastoitsis G, Furfine ES, Barnes TM.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3913-8. doi: 10.1073/pnas.1217996110. Epub 2013 Feb 19.

19.

Subversion of cytokine networks by virally encoded decoy receptors.

Epperson ML, Lee CA, Fremont DH.

Immunol Rev. 2012 Nov;250(1):199-215. doi: 10.1111/imr.12009. Review.

20.

Biomolecular dynamics: order-disorder transitions and energy landscapes.

Whitford PC, Sanbonmatsu KY, Onuchic JN.

Rep Prog Phys. 2012 Jul;75(7):076601. doi: 10.1088/0034-4885/75/7/076601. Epub 2012 Jun 28.

Supplemental Content

Support Center